As the amino acid sequencing of Adgrf1 are highly conserved in humans and mice, targeting Adgrf1 may serve as a novel therapeutic approach for the treatment of NAFLD patients. Here, ADGRF1 is linked to metabolic dysfunction-associated steatotic liver disease.